Wockhardt, Strides Arcolab and Ranbaxy Laboratories have rallied between 10-20%, while Aurobindo Pharma, Cadila Healthcare, Cipla, Biocon, Lupin and Divi’s Laboratories are trading higher in the range of 2-6% on the BSE.
The BSE pharmaceutical index S&P BSE Healthcare, the largest gainer among sectoral indices, is up 2.14% compared to 0.35% rise in benchmark S&P BSE Sensex at 1230 hours.
According to a recent Economic Times report, the US Food and Drug Administration (US FDA) has detected no impurity in the Indian version of cholesterol-lowering generic drug Atorvastat in recent tests.
That may be seen “as a positive” for companies as facilities of many top Indian drug firms such as Ranbaxy, Wockhardt, Sun Pharma have been recently red flagged by the US FDA.
Among the individual stocks, Wockhardt, the largest gainer among the pack, is locked in upper circuit of 20% at Rs 552 on the BSE. The company is facing various regulatory issues, including USFDA import alert at Waluj and Chikalthana units.
The stock has seen huge trading activity with a combined 8.2 million shares already changed hands and there are pending buy orders for 602,700 shares on the BSE and NSE.
Strides Arcolab has soared 13% to Rs 434, followed by Ranbaxy Laboratories (11% at Rs 410) and Aurobindo Pharma (6% to Rs 569).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)